{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:12:23Z","timestamp":1776255143777,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"DOI":"10.1186\/s13561-026-00732-0","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:24:28Z","timestamp":1773051868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The complex price setting and reimbursement of non-industrial advanced therapy medicinal products"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-2934","authenticated-orcid":false,"given":"Zuzana","family":"\u0160pac\u00edrov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0680-7353","authenticated-orcid":false,"given":"Juan Carlos","family":"Rejon-Parrilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-6554","authenticated-orcid":false,"given":"Jaime","family":"Esp\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"732_CR1","unstructured":"European Medicines Agency (EMA). Advanced therapy medicinal products: Overview. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview. Accessed 30 Jul 2025."},{"key":"732_CR2","doi-asserted-by":"publisher","unstructured":"Rejon-Parrilla JC, Espin J, Garner S, Kniazkov S, Epstein D. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1199500","DOI":"10.3389\/fphar.2023.1199500"},{"key":"732_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2016.08.012","author":"M Abou-El-Enein","year":"2016","unstructured":"Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell. 2016. https:\/\/doi.org\/10.1016\/j.stem.2016.08.012.","journal-title":"Cell Stem Cell"},{"key":"732_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.12.014","author":"C Iglesias-L\u00f3pez","year":"2023","unstructured":"Iglesias-L\u00f3pez C, Agust\u00ed A, Vallano A, Obach M. Financing and reimbursement of approved advanced therapies in several European countries. Value Heal. 2023. https:\/\/doi.org\/10.1016\/j.jval.2022.12.014.","journal-title":"Value Heal"},{"key":"732_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.73","author":"S de Wilde","year":"2016","unstructured":"de Wilde S, Guchelaar HJ, Zandvliet ML, Meij P. Clinical development of gene- and cell-based therapies: overview of the European landscape. Mol Ther Methods Clin Dev. 2016. https:\/\/doi.org\/10.1038\/mtm.2016.73.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"732_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.12.005","author":"E Olesti","year":"2024","unstructured":"Olesti E, Nuevo Y, Bachiller M, Guillen E, Bascuas J, Varea S, et al. Academic challenges on advanced therapy medicinal products\u2019 development: a regulatory perspective. Cytotherapy. 2024. https:\/\/doi.org\/10.1016\/j.jcyt.2023.12.005.","journal-title":"Cytotherapy"},{"key":"732_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jcyt.2020.08.011","volume":"22","author":"A Hills","year":"2020","unstructured":"Hills A, Awigena-Cook J, Genenz K, Ostertag M, Butler S, Eggimann AV, et al. An assessment of the hospital exemption landscape across European member states: regulatory frameworks, use and impact. Cytotherapy. 2020;22:772\u2013e7791. https:\/\/doi.org\/10.1016\/j.jcyt.2020.08.011.","journal-title":"Cytotherapy"},{"key":"732_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.10.003","author":"RMT ten Ham","year":"2018","unstructured":"ten Ham RMT, Hoekman J, H\u00f6vels AM, Broekmans AW, Leufkens HGM, Klungel OH. Challenges in advanced therapy medicinal product development: A survey among companies in Europe. Mol Ther Methods Clin Dev. 2018. https:\/\/doi.org\/10.1016\/j.omtm.2018.10.003.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"732_CR9","unstructured":"Official Journal of the European Union. Regulation (EC) No 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004. 2007; https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF. Accessed 3 Dec 2024."},{"key":"732_CR10","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2020-0008","author":"DGM Coppens","year":"2020","unstructured":"Coppens DGM, Gardarsdottir H, Bruin MLD, Meij P, Gm Leufkens H, Hoekman J. Regulating advanced therapy medicinal products through the hospital exemption: an analysis of regulatory approaches in nine EU countries. Regen Med. 2020. https:\/\/doi.org\/10.2217\/rme-2020-0008.","journal-title":"Regen Med"},{"key":"732_CR11","unstructured":"European Medicines Agency (EMA). EMA pilot offers enhanced support to academic and non-profit developers of advanced therapy medicinal products. 2022. https:\/\/www.ema.europa.eu\/en\/news\/ema-pilot-offers-enhanced-support-academic-non-profit-developers-advanced-therapy-medicinal-products. Accessed 22 Jun 2025."},{"key":"732_CR12","unstructured":"European Medicines Agency. Progress update on pilot for academic and non-profit develpers of advanced therapy medicines. https:\/\/www.ema.europa.eu\/en\/news\/progress-update-pilot-academic-non-profit-developers-advanced-therapy-medicines. Accessed 27 Sep 2024."},{"key":"732_CR13","unstructured":"European Medicines Agency. Q&A on EMA pilot offering enhanced support to academic and non-profit developers of Advanced Therapy Medicinal Products (ATMPs). 2024; https:\/\/pink.citeline.com\/-\/media\/supporting-documents\/pink-sheet\/2023\/02\/p0223ema_14.pdf. Accessed 25 Aug 2025."},{"key":"732_CR14","unstructured":"European Commission: European Health and, Agency DE, Rod\u00e9s S\u00e1nchez M, Griepink M, Van der Feen JF, Cuartas-Acosta A et al. Study on the Hospital Exemption - Final Report, Publications Office of the European Union. 2025. https:\/\/data.europa.eu\/doi\/10.2925\/6644732. Accessed 7 Aug 2025."},{"key":"732_CR15","unstructured":"Ministerio de Sanidad. Propuesta de precio de medicamentos de terapia avanzada de fabricaci\u00f3n no industrial. Ficha normalizada para el c\u00e1lculo del precio. 2019. https:\/\/www.sanidad.gob.es\/areas\/farmacia\/infoMedicamentos\/terapiasAvanzadas\/docs\/20191014_Anexo1_Propuesta_precio_MTA_no_industrial_SNS_CISNS.pdf.Accessed 7 Jul 2025."},{"key":"732_CR16","unstructured":"Sarid-Krebs L, Denzinger C, Buljovcic Z. Jul. Reimbursement of ATMPs in Germany: Challenges, opportunities and key initiatives. Biophrama Excell. https:\/\/www.biopharma-excellence.com\/articles\/reimbursement-of-atmps-in-germany-challenges-opportunities-and-key-initiatives\/. Accessed 10 2025."},{"key":"732_CR17","unstructured":"FAST. Guidebook for ATMP Development: From Research to Clinical Practica in the Netherlands. 2024; https:\/\/www.vereniginginnovatievegeneesmiddelen.nl\/wp-content\/uploads\/2024\/11\/FAST_Guidebook-ATMP.pdf. Accessed 10 Jul 2025."},{"key":"732_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.1987219","author":"S van der Schans","year":"2022","unstructured":"van der Schans S, De Loos F, Boersma C, Postma MJ, B\u00fcller H. A novel perspective on pharmaceutical R&D costs: opportunities for reductions. Expert Rev Pharmacoeconomics Outcomes Res. 2022. https:\/\/doi.org\/10.1080\/14737167.2022.1987219.","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"732_CR19","unstructured":"BOTPLUS. https:\/\/botplusweb.farmaceuticos.com\/. Accessed 30 Jun 2025."},{"key":"732_CR20","doi-asserted-by":"publisher","DOI":"10.1145\/2745802.2745818","author":"D Badampudi","year":"2015","unstructured":"Badampudi D, Wohlin C, Petersen K. Experiences from using snowballing and database searches in systematic literature studies. EASE\u201915 Proc 19th Int Conf onEvaluation Assess Softw Eng. 2015. https:\/\/doi.org\/10.1145\/2745802.2745818.","journal-title":"EASE\u201915 Proc 19th Int Conf onEvaluation Assess Softw Eng"},{"key":"732_CR21","unstructured":"Grant worth \u20ac30 million for UMCG research into promising new cancer treatment. 2020; https:\/\/www.rug.nl\/news\/2020\/09\/grant-worth-30-million-for-umcg-research-into-promising-new-cancer-treatment. Accessed 3 Oct 2025."},{"key":"732_CR22","unstructured":"Developing a new CAR-T Therapy. 2025; https:\/\/oslocancercluster.no\/news\/developing-a-new-cart-therapy. Accessed 15 Oct 2025."},{"key":"732_CR23","unstructured":"Ficha t\u00e9cnica del medicamento NC1. 2024; https:\/\/www.aemps.gob.es\/investigacionClinica\/terapiasAvanzadas\/docs\/NC1_ficha-tecnica.pdf. Accessed 9 Jan 2025."},{"key":"732_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01962-0","author":"F S\u00e1nchez-Guijo","year":"2023","unstructured":"S\u00e1nchez-Guijo F, Avenda\u00f1o-Sol\u00e1 C, Badim\u00f3n L, Bueren JA, Canals JM, Delgadillo J, et al. Role of hospital exemption in europe: position paper from the Spanish advanced therapy network (TERAV). Bone Marrow Transpl. 2023. https:\/\/doi.org\/10.1038\/s41409-023-01962-0.","journal-title":"Bone Marrow Transpl"},{"key":"732_CR25","unstructured":"Agencia espa\u00f1ola de medicamentos y productos Sanitarios. Listado de autorizaci\u00f3n de uso. 2025; https:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/medicamentos-de-fabricacion-no-industrial\/terapias-avanzadas\/listado-de-autorizacion-de-uso\/. Accessed 10 Oct 2025."},{"key":"732_CR26","unstructured":"Rod\u00e9s S\u00e1nchez M, Griepink M, Van der Feen J, Cuartas-Acosta A, Jansana A, Berry M et al. Study on the Hospital Exemption. Member State Reports. Annex 1 to the Final Report. 2025; https:\/\/euagenda.eu\/publications\/study-on-the-hospital-exemption-member-state-reports. Accessed 15 Oct 2025."},{"key":"732_CR27","unstructured":"BIFIMED: Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos - Nomencl\u00e1tor. NC1. Ministerio de Sanidad. 2025; https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=724688. Accessed 21 Jul 2025."},{"key":"732_CR28","unstructured":"Precio definitivo para la primera terapia avanzada p\u00fablica: 21.577 euros. Redacci\u00f3n M\u00e9dica. 2019; https:\/\/www.redaccionmedica.com\/secciones\/ministerio-sanidad\/precio-definitivo-para-la-primera-terapia-avanzada-publica-21-577-euros-5705. Accessed 10 Jul 2025."},{"key":"732_CR29","unstructured":"Ficha t\u00e9cnica de ARI-0001. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). https:\/\/www.aemps.gob.es\/investigacionClinica\/terapiasAvanzadas\/docs\/ARI-0001_ficha-tecnica.pdf. Accessed 11 Jul 2025."},{"key":"732_CR30","unstructured":"BIFIMED. Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos - Nomencl\u00e1tor. ARI-0001. Ministerio de Sanidad. https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=730288. Accessed 21 Jul 2025."},{"key":"732_CR31","unstructured":"Ortega E. La primera CART p\u00fablica ARI 0001 ya tiene precio: 89.270 euros. Redacci\u00f3n M\u00e9dica. 2021; https:\/\/www.redaccionmedica.com\/secciones\/hematologia-y-hemoterapia\/la-primera-cart-publica-ari-0001-ya-tiene-precio-89-270-euros-7483. Accessed 22 Jun 2025."},{"key":"732_CR32","unstructured":"Ficha T\u00e9cnica o Resumen de las Caracter\u00edsticas del Producto. CEMTROCELL. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). https:\/\/www.aemps.gob.es\/investigacionClinica\/terapiasAvanzadas\/docs\/FT-Cemtrocell.pdf. Accessed 21 Jul 2025."},{"key":"732_CR33","unstructured":"Ficha t\u00e9cnica. Piel humana obtenida por ingenier\u00eda de tejidos. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). https:\/\/www.aemps.gob.es\/investigacionClinica\/terapiasAvanzadas\/docs\/HH_FT_001_003_Ficha-tecnica-Piel-Humana-08072024.pdf. Accessed 21 Jul 2025."},{"key":"732_CR34","unstructured":"BIFIMED. Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos - Nomencl\u00e1tor. Piel humana obtenida por ingenier\u00eda de tejidos. Ministerio de Sanidad. https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=765258. Accessed 21 Jul 2025."},{"key":"732_CR35","unstructured":"Ficha t\u00e9cnica. ARI0002h. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). https:\/\/www.aemps.gob.es\/investigacionClinica\/terapiasAvanzadas\/docs\/ARI0002h_Fichat\u00e9cnica_Final.pdf. Accessed 21 Jul 2025."},{"key":"732_CR36","unstructured":"BIFIMED: Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos - Nomencl\u00e1tor. ARI-0002\u00a0h. Ministerio de Sanidad. 2025; https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=607821. Accessed 21 Jul 2025."},{"key":"732_CR37","unstructured":"German Institute for the Hospital Remuneration SYstem (InEK). NUB application. https:\/\/reimbursement.institute\/en\/nub-application\/. Accessed 11 Jul 2025."},{"key":"732_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.73","author":"S de Wilde","year":"2016","unstructured":"de Wilde S, Veltrop-Duits L, Hoozemans-Strik M, Ras T, Blom-Veenman J, Guchelaar H-J, et al. Hurdles in clinical implementation of academic advanced therapy medicinal products: A National evaluation. Cytotherapy. 2016. https:\/\/doi.org\/10.1038\/mtm.2016.73.","journal-title":"Cytotherapy"},{"key":"732_CR39","unstructured":"Agenzia Italiana del Farmaco (AIFA). Linee Guida per la Compilazione del Dossier a Supporto della Domanda di Rimborsabilit\u00e0 e Prezzo di un Medicinale. 2019; https:\/\/www.aifa.gov.it\/documents\/20142\/1283800\/Linee_guida_dossier_domanda_rimborsabilita.pdf. Accessed 23 Jul 2025."},{"key":"732_CR40","unstructured":"Firth I, Schirrmacher H, Hampson G, Towse A. Key considerations for early access schemes for one-time therapies. London: Office of Health Economics. 2021; https:\/\/www.ohe.org\/publications\/key-considerations-early-access-schemes-single-administration-one-time-therapies\/. Accessed 23 Oct 2025."},{"key":"732_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.03.432","author":"RMT ten Ham","year":"2020","unstructured":"ten Ham RMT, H\u00f6vels AM, Hoekman J, Frederix GWJ, Leufkens HGM, Klungel OH, et al. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy. 2020. https:\/\/doi.org\/10.1016\/j.jcyt.2020.03.432.","journal-title":"Cytotherapy"},{"key":"732_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s42977-020-00025-5","author":"S Annett","year":"2021","unstructured":"Annett S. Pharmaceutical drug development: high drug prices and the hidden role of public funding. Biol Futur. 2021. https:\/\/doi.org\/10.1007\/s42977-020-00025-5.","journal-title":"Biol Futur"},{"key":"732_CR43","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.24934.1","author":"RM Conti","year":"2020","unstructured":"Conti RM, David FS. Public research funding and pharmaceutical prices: do Americans pay twice for drugs? F1000Research. 2020. https:\/\/doi.org\/10.12688\/f1000research.24934.1.","journal-title":"F1000Research"},{"key":"732_CR44","unstructured":"What role should governments play in setting rewards for medical innovation? J Intellect Prop Entertain Law. 2021; https:\/\/jipel.law.nyu.edu\/what-role-should-governments-play-in-setting-rewards-for-medical-innovation\/. Accessed 25 Aug 2025."},{"key":"732_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/qje\/qjv012","author":"M Kremer","year":"2015","unstructured":"Kremer M, Snyder C. Preventives versus treatments. Q J Econ. 2015. https:\/\/doi.org\/10.1093\/qje\/qjv012.","journal-title":"Q J Econ"},{"key":"732_CR46","unstructured":"Bookstaber P. What Is Cost Plus Pricing? How Do You Use It In Sales? 360 Blog. 2024; https:\/\/www.salesforce.com\/blog\/cost-plus-pricing\/. Accessed 24 Jul 2025."},{"key":"732_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01276-2","author":"E Gon\u00e7alves","year":"2022","unstructured":"Gon\u00e7alves E. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions. Eur J Heal Econ. 2022. https:\/\/doi.org\/10.1007\/s10198-021-01276-2.","journal-title":"Eur J Heal Econ"},{"key":"732_CR48","unstructured":"Truelove C. A Way Forward for ATMPs: How Pharma and Payers Can Determine Value-Based Agreements. Value Outcomes Spotlight. An HEOR news magazine. 2022. https:\/\/www.ispor.org\/publications\/journals\/value-outcomes-spotlight\/vos-archives\/issue\/view\/global-price-transparency\/a-way-forward-for-atmps-how-pharma-and-payers-can-determine-value-based-agreements.Accessed 4 Dec 2025."},{"key":"732_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33156","author":"T Ran","year":"2020","unstructured":"Ran T, Eichm\u00fcller SB, Schmidt P, Schlander M. Cost of decentralized CAR T-cell production in an academic nonprofit setting. Int J Cancer. 2020. https:\/\/doi.org\/10.1002\/ijc.33156.","journal-title":"Int J Cancer"},{"key":"732_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-025-00576-9","author":"JC Rejon-Parrilla","year":"2025","unstructured":"Rejon-Parrilla JC, Epstein D, Mestre-Ferrandiz J, Espin J. A framework for considering the role of the public sector in R&D of health technology. Pharmaceut Med. 2025. https:\/\/doi.org\/10.1007\/s40290-025-00576-9.","journal-title":"Pharmaceut Med"},{"key":"732_CR51","unstructured":"European Commission. Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the Union code relating to medicinal products for human use, and repealing Directive 2001\/83\/EC and Directive 2009\/35\/EC. 2023; https:\/\/eur-lex.europa.eu\/resource.html?uri=cellar:bfcb9e00-e437-11ed-a05c-01aa75ed71a1.0001.02\/DOC_1&format=PDF. Accessed 30 Jul 2025."},{"key":"732_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0465-1","author":"JC Jacobs","year":"2017","unstructured":"Jacobs JC, Barnett PG. Emergent challenges in determining costs for economic evaluations. PharmacoEconomics. 2017. https:\/\/doi.org\/10.1007\/s40273-016-0465-1.","journal-title":"PharmacoEconomics"},{"key":"732_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01157-9","author":"Z \u0160pac\u00edrov\u00e1","year":"2020","unstructured":"\u0160pac\u00edrov\u00e1 Z, Epstein D, Garc\u00eda-Moch\u00f3n L, Rovira J, Olry de Labry Lima A, Esp\u00edn J. A general framework for classifying costing methods for economic evaluation of health care. Eur J Heal Econ. 2020. https:\/\/doi.org\/10.1007\/s10198-019-01157-9.","journal-title":"Eur J Heal Econ"},{"key":"732_CR54","doi-asserted-by":"publisher","DOI":"10.5146\/tjpath.2013.01141","author":"FA Ergun","year":"2013","unstructured":"Ergun FA, Agirbas I, Kuzu I. Activity-based costing for pathology examinations and comparison with the current pricing system in Turkey. Turkish J Pathol. 2013. https:\/\/doi.org\/10.5146\/tjpath.2013.01141.","journal-title":"Turkish J Pathol"},{"key":"732_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01444-y","author":"Z \u0160pac\u00edrov\u00e1","year":"2022","unstructured":"\u0160pac\u00edrov\u00e1 Z, Epstein D, Esp\u00edn J. Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European healthcare and social cost database. Eur J Heal Econ. 2022. https:\/\/doi.org\/10.1007\/s10198-022-01444-y.","journal-title":"Eur J Heal Econ"},{"key":"732_CR56","unstructured":"European Observatory on Health Systems and Policies. Austria. Health Systems in Transition (HiT) profile. 2021; https:\/\/eurohealthobservatory.who.int\/monitors\/health-systems-monitor\/countries-hspm\/hspm\/austria-2018\/financing\/payment-mechanisms? Accessed 20 Oct 2025."},{"key":"732_CR57","unstructured":"Neue Finanzierungsmodelle f\u00fcr Gentherapien. 2023; https:\/\/www.medmedia.at\/pharm-austria\/neue-finanzierungsmodelle-fuer-gentherapien\/. Accessed 20 Oct 2025."}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00732-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00732-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00732-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:27:35Z","timestamp":1776252455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13561-026-00732-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00732-0","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}